Showing 5091-5100 of 6661 results for "".
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in
- Warts and All: Novan Files Chapter 11, Sells Assetshttps://practicaldermatology.com/news/warts-and-all-novan-files-chapter-11-sells-assets/2461870/Novan is selling all of its assets, including Berdazimer Gel, 10.3% (SB206), and has filed for Chapter 11 Protection. The Company entered into a stalking horse asset purchase agreement (APA) with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief unde
- News You Can Use: GW, Pfizer Offering Grants to Improve Access to Teledermatology in Underserved Areashttps://practicaldermatology.com/news/news-you-can-use-gw-pfizer-offering-grants-to-improve-access-to-teledermatology-in-underserved-areas/2461865/The George Washington University (GW) School of Medicine and Health Sciences (SMHS) and Pfizer Global Medical Grants are collaborating to offer a grant opportunity focused on broad implementation of GW’s Teledermatology Help Desk Clinic model in underserved areas across the United States.</
- Revian Red Hair Growth System Takes on CCCA in Second Studyhttps://practicaldermatology.com/news/revian-red-hair-growth-system-takes-on-ccca-in-second-study/2461864/Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wirel
- Cetuximab Plus Radiation May Be Effective Treatment for Advanced Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/cetuximab-plus-radiation-may-be-effective-treatment-for-advanced-squamous-cell-skin-cancer/2461860/Cetuximab plus radiotherapy may be an effective treatment option for locally advanced cutaneous squamous cell cancers (laCSCC), with manageable toxicity, according to a study in Oncotarget. Cetuximab is
- Biosimilar Update: FDA Accepts Dr. Reddy’s Proposed Rituximab Biosimilar Application for Reviewhttps://practicaldermatology.com/news/biosimilar-update-fda-accepts-dr-reddys-proposed-rituximab-biosimilar-application-for-review/2461859/Dr. Reddy’s Laboratories Ltd’s Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (FDA). This closely follows acceptance of its rituximab biosimi
- Opzelura Cream Safely Eases AD in Young Kidshttps://practicaldermatology.com/news/opzelura-cream-safely-eases-ad-in-young-kids/2461857/Incyte’s ruxolitinib cream (Opzelura) cleared skin in significantly more kids with atopic dermatitis (AD) than a nonmedicated topical control, a new study shows. The study, which included 300 kids aged ≥2 to <12, met its primary endpoint and showed signi
- GlobalSkin’s GRIDD Study to Measure True Impact of Skin Diseases Across the Globehttps://practicaldermatology.com/news/globalskins-gridd-study-to-measure-true-impact-of-skin-diseases-across-the-globe/2461856/The International Alliance of Dermatology Patient Organizations (GlobalSkin), in partnership with Cardiff University (UK), and University Medical Centre Hamburg-Eppendorf (Germany), launched the Global Research on the
- Novel Peptide T14 May Reflect Age and Photoaging in Human Skinhttps://practicaldermatology.com/news/novel-peptide-t14-may-reflect-age-and-photo-aging-in-human-skin/2461843/A novel peptide ‘T14’ may reflect age and photoaging in human skin, according to a study in Aging. T14 is a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE). Once cleav
- WCD News: Spesolimab Prevents GPP Flareshttps://practicaldermatology.com/news/wcd-news-spesolimab-prevents-gpp-flares/2461841/Spesolimab reduced the risk of generalized pustular psoriasis (GPP) flares flares by 84% over 48 weeks compared to placebo, according to late-breaking data from the EFFISAYIL™ 2 trial presebted at the at the 25th World Congress of Dermatology (WCD) in Singapore. Fur